Perspective Therapeutics (NYSE:CATX) Earns “Outperform” Rating from Wedbush

Perspective Therapeutics (NYSE:CATX)‘s stock had its “outperform” rating reaffirmed by investment analysts at Wedbush in a research note issued on Wednesday, Marketbeat reports. They presently have a $11.00 target price on the stock. Wedbush’s price target suggests a potential upside of 378.26% from the stock’s current price.

CATX has been the topic of several other research reports. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. Scotiabank initiated coverage on Perspective Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Perspective Therapeutics in a report on Wednesday, March 19th. Cantor Fitzgerald raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. Finally, Brookline Capital Management raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Perspective Therapeutics has an average rating of “Buy” and an average price target of $14.44.

Perspective Therapeutics Stock Performance

CATX opened at $2.30 on Wednesday. Perspective Therapeutics has a twelve month low of $2.22 and a twelve month high of $19.05. The company has a 50-day moving average price of $2.96 and a 200 day moving average price of $6.51.

Institutional Trading of Perspective Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Perspective Therapeutics by 19.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,150 shares of the company’s stock worth $224,000 after acquiring an additional 11,472 shares during the period. Velan Capital Investment Management LP purchased a new position in shares of Perspective Therapeutics during the 4th quarter worth $1,595,000. Squarepoint Ops LLC acquired a new stake in shares of Perspective Therapeutics during the 4th quarter worth about $626,000. Wexford Capital LP acquired a new stake in shares of Perspective Therapeutics during the 4th quarter worth about $64,000. Finally, Two Sigma Advisers LP purchased a new stake in Perspective Therapeutics in the 4th quarter valued at about $484,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.